Compared with other antidiabetic medications, semaglutide was linked to a significantly lower risk of opioid overdose in ...

A new expert review endorses GLP-1 RAs and other medications for sustainable weight loss in children with obesity and MASLD.

Despite the current downward trend, long-term investors may stay invested in NVO stock due to strong demand for its GLP-1 ...

Similarly, among those without diabetes who were prescribed weight-loss medications, the uptake of tirzepatide and semaglutide rose dramatically, while older agents including liraglutide and ...

AFTER “fighting a losing battle” with her weight for years, a mum shed 11st in a matter months with the help of weight loss ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

If you are taking a weight loss medication such as Ozempic, Wegovy, or Zepbound for obesity or other health concerns, you may ...

Novo Nordisk has filed another Citizen's Petition with the FDA seeking to block compounding pharmacies in the US from making versions of one of its GLP-1 agonist drugs. The latest attempt focuses ...

Liraglutide is on the market as Victoza for diabetes and Saxenda for obesity. It has been largely superseded, however, by Novo Nordisk's semaglutide-based therapies, Ozempic for diabetes and ...

Dispensations of tirzepatide and semaglutide increased significantly in recent years while the use of other glucose-lowering ...

Weight loss injections boost the glucagon-like peptide-1 (GLP-1) hormone, which is a naturally produced hormone in the ...

Discover Mounjaro Tirzepatide's impact on obesity in India post its March launch. Get insights on effectiveness against ...